BRIEF-Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

Wed Oct 12, 2016 6:13am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Oct 12 (Reuters) - Prometic Life Sciences Inc :

* Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

* Prometic Life Sciences-significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment

* Prometic Life Sciences Inc - liver enzymes reduced to within normal ranges in all patients that completed 12 weeks of PBI-4050 treatment

* Prometic Life Sciences Inc - alström syndrome clinical program to be expanded to include further sites throughout europe and north america

* Prometic Life Sciences-drug safety monitoring board recommended patient enrolment should continue in co's ongoing alström syndrome phase 2 clinical trial Source text for Eikon: Further company coverage: